Susan Berson and Brent Henry Recognized as Health Care Trailblazers by the National Law Journal
Filter by:
Mintz Continues To Expand Leading Life Sciences And Private Equity Capabilities In Toronto
April 12, 2023
TORONTO – Mintz continues to grow in Canada and extend its market-leading life sciences and private equity capabilities. The addition of Partners Matthew Atkey and Brad Tartick, Special Counsel Bernard Kwasniewski and Of Counsel Matthew Imrie, will bolster Mintz’s premier capital markets, M&A, funds, and employment and pensions-focused practices.
WASHINGTON, D.C. – Mintz’s Private Equity Co-Chair, Matthew T. Simpson is one of a group of experts arranged by the Public International Law & Policy Group (PILPG) to develop a series of tools and resources to assist with potential future ceasefire negotiations between Ukraine and Russia.
Mintz Continues Bay Street Legal Talent Raid, Hiring Four Lawyers From Torys, Dentons
April 12, 2023
The Globe and Mail featured the arrival of Partners Matthew Atkey and Brad Tartick, Special Counsel Bernard Kwasniewski and Of Counsel Matthew Imrie who will join Michael Akkawi, Cheryl Reicin, Mitch Frazer, Eric Foster, and Lee Johnson in the firm's Toronto office.
Mintz Taps Ex-FCC Legal Adviser As Technology Co-Chair
April 12, 2023
Law360 featured Angela Y. Kung's appointment to co-lead the firm’s Technology, Communications & Media practice.
HHS Proposes Rule Shoring Up HIPAA To Protect Reproductive Health Data, Including Around abortions
April 12, 2023
Health Care Dive interviewed Member Dianne Bourque about the Biden administration's proposed new rule that would ban health care entities from sharing patient information.
Mintz Advises Underwriters of Viking’s $287.5 Million Public Offering of Common Stock
April 10, 2023
NEW YORK – Mintz represented the syndicate of underwriters led by William Blair & Company, L.L.C., in the public offering of 17,242,000 shares of common stock of Viking Therapeutics, Inc. (“Viking”) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, at an initial offering price of $14.50 per share.